Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
STADA Arzneimittel AG acquired Belgian generics distributor Eurogenerics SA (estimated at approximately $55 million, comprising $25 million cash and $30 million in stock) around 1990-91, an early step in building its pan-European generics distribution network from its German cooperative base.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| STADA Arzneimittel / Eurogenerics (this deal) | 1991 | $55M | 48 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 1991 deals · Neurology deals